Literature DB >> 19233857

Hypertrophic obstructive cardiomyopathy-alcohol septal ablation vs. myectomy: a meta-analysis.

Mahboob Alam1, Hisham Dokainish, Nasser M Lakkis.   

Abstract

AIMS: Our purpose is to conduct a meta-analysis of all published studies comparing alcohol septal ablation (ASA) and myectomy (MM) for drug refractory hypertrophic obstructive cardiomyopathy (HOCM). Alcohol septal ablation is a less invasive alternative to MM for relief of symptoms in patients with drug refractory HOCM. METHODS AND
RESULTS: An extensive search of PubMed identified five non-randomized studies comparing ASA and MM. Of 351 patients studied, 183 underwent ASA and 168 underwent MM. Patients undergoing ASA were older (mean age 54.4 +/- 6.3 vs. 45.0 +/- 4.4 years, P = 0.02). All patients were in New York Heart Association (NYHA) class II-IV. Baseline left ventricular outflow tract (LVOT) gradient was comparable (81.4 +/- 14.3 mmHg in ASA vs. 77.4 +/- 15.5 mmHg in MM, P = 0.2). Although resting LVOT gradient after septal reduction therapy in both groups was <20 mmHg at follow-up, patients undergoing MM had lower LVOT gradient (18.2 +/- 6.7 vs. 10.8 +/- 6.3 mmHg, P < 0.001). Patients in both groups had comparable improvement in NYHA class (1.5 +/- 0.3 in ASA vs. 1.3 +/- 0.2, P = 0.2) at follow-up. A higher percentage of patients undergoing ASA required permanent pacemaker (PPM) implantation for complete heart block (18.4 +/- 7.9 vs. 3.3 +/- 3.9%, P = 0.04). There was no significant in-hospital mortality difference between the two groups.
CONCLUSION: Alcohol septal ablation and MM provide significant reduction in LVOT gradient and NYHA functional class on mid-term follow-up. A higher percentage of patients required PPM after ASA. Randomized trials are needed to confirm current findings.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19233857     DOI: 10.1093/eurheartj/ehp016

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  23 in total

Review 1.  Pacing for drug-refractory or drug-intolerant hypertrophic cardiomyopathy.

Authors:  Mohammed Qintar; Abdulrahman Morad; Hazem Alhawasli; Khaled Shorbaji; Belal Firwana; Adib Essali; Waleed Kadro
Journal:  Cochrane Database Syst Rev       Date:  2012-05-16

2.  Extended Septal Myectomy for Hypertrophic Obstructive Cardiomyopathy in Children and Adolescents.

Authors:  Haitao Xu; Jun Yan; Qiang Wang; Dianyuan Li; Hongwei Guo; Shoujun Li; Ju Wang; Song Lou; Qingdong Zeng
Journal:  Pediatr Cardiol       Date:  2016-05-09       Impact factor: 1.655

3.  Optimal gradient reduction after alcohol septal ablation: a case report with anatomical and practical determinants.

Authors:  R C Steggerda; J C Balt; J M Ten Berg
Journal:  Neth Heart J       Date:  2011-06       Impact factor: 2.380

4.  Surgery for hypertrophic cardiomyopathy.

Authors:  James J Wu; Michael Seco; Caroline Medi; Chris Semsarian; David R Richmond; Joseph A Dearani; Hartzell V Schaff; Michael J Byrom; Paul G Bannon
Journal:  Biophys Rev       Date:  2015-01-10

5.  Basal infarct location but not larger infarct size is associated with a successful outcome after alcohol septal ablation in patients with hypertrophic obstructive cardiomyopathy: a cardiovascular magnetic resonance imaging study.

Authors:  Robbert C Steggerda; Christiane A Geluk; Wessel Brouwer; Albert C van Rossum; Jurriën M Ten Berg; Maarten P van den Berg
Journal:  Int J Cardiovasc Imaging       Date:  2015-02-01       Impact factor: 2.357

Review 6.  Hypertrophic cardiomyopathy: diagnosis, risk stratification and treatment.

Authors:  Daniel L Jacoby; Eugene C DePasquale; William J McKenna
Journal:  CMAJ       Date:  2012-10-29       Impact factor: 8.262

7.  Alcohol ablation of a coronary artery fistula supplying a tumor-like malformation as the cause of angina.

Authors:  O Akkus; A Deniz; T Balli; O Kaypakli; M Demir; M Demirtas
Journal:  Herz       Date:  2013-01-18       Impact factor: 1.443

Review 8.  Current status and future perspectives on alcohol septal ablation for hypertrophic obstructive cardiomyopathy.

Authors:  Rami N Khouzam; Srihari S Naidu
Journal:  Curr Cardiol Rep       Date:  2014-05       Impact factor: 2.931

9.  Minimally Invasive Versus Full-Sternotomy Septal Myectomy for Hypertrophic Cardiomyopathy.

Authors:  Farah N Musharbash; Matthew R Schill; Vivek H Hansalia; Richard B Schuessler; Jeremy E Leidenfrost; Spencer J Melby; Ralph J Damiano
Journal:  Innovations (Phila)       Date:  2018 Jul/Aug

10.  Alcohol Septal Ablation for the Treatment of Hypertrophic Obstructive Cardiomyopathy.

Authors:  Constantinos O'Mahony; Saidi A Mohiddin; Charles Knight
Journal:  Interv Cardiol       Date:  2014-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.